137 related articles for article (PubMed ID: 27540016)
1. The Novel Tubulin-Binding Checkpoint Activator BAL101553 Inhibits EB1-Dependent Migration and Invasion and Promotes Differentiation of Glioblastoma Stem-like Cells.
Bergès R; Tchoghandjian A; Honoré S; Estève MA; Figarella-Branger D; Bachmann F; Lane HA; Braguer D
Mol Cancer Ther; 2016 Nov; 15(11):2740-2749. PubMed ID: 27540016
[TBL] [Abstract][Full Text] [Related]
2. EB1-dependent long survival of glioblastoma-grafted mice with the oral tubulin-binder BAL101553 is associated with inhibition of tumor angiogenesis.
Bergès R; Tchoghandjian A; Sergé A; Honoré S; Figarella-Branger D; Bachmann F; Lane HA; Braguer D
Oncotarget; 2020 Feb; 11(8):759-774. PubMed ID: 32165998
[TBL] [Abstract][Full Text] [Related]
3. End-binding 1 protein overexpression correlates with glioblastoma progression and sensitizes to Vinca-alkaloids in vitro and in vivo.
Berges R; Baeza-Kallee N; Tabouret E; Chinot O; Petit M; Kruczynski A; Figarella-Branger D; Honore S; Braguer D
Oncotarget; 2014 Dec; 5(24):12769-87. PubMed ID: 25473893
[TBL] [Abstract][Full Text] [Related]
4. The novel microtubule-destabilizing drug BAL27862 binds to the colchicine site of tubulin with distinct effects on microtubule organization.
Prota AE; Danel F; Bachmann F; Bargsten K; Buey RM; Pohlmann J; Reinelt S; Lane H; Steinmetz MO
J Mol Biol; 2014 Apr; 426(8):1848-60. PubMed ID: 24530796
[TBL] [Abstract][Full Text] [Related]
5. Treating ICB-resistant glioma with anti-CD40 and mitotic spindle checkpoint controller BAL101553 (lisavanbulin).
Genoud V; Espinoza FI; Marinari E; Rochemont V; Dietrich PY; McSheehy P; Bachmann F; Lane HA; Walker PR
JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34403371
[TBL] [Abstract][Full Text] [Related]
6. Epothilone B inhibits migration of glioblastoma cells by inducing microtubule catastrophes and affecting EB1 accumulation at microtubule plus ends.
Pagano A; Honoré S; Mohan R; Berges R; Akhmanova A; Braguer D
Biochem Pharmacol; 2012 Aug; 84(4):432-43. PubMed ID: 22634050
[TBL] [Abstract][Full Text] [Related]
7. Proscillaridin A exerts anti-tumor effects through GSK3β activation and alteration of microtubule dynamics in glioblastoma.
Berges R; Denicolai E; Tchoghandjian A; Baeza-Kallee N; Honore S; Figarella-Branger D; Braguer D
Cell Death Dis; 2018 Sep; 9(10):984. PubMed ID: 30250248
[TBL] [Abstract][Full Text] [Related]
8. Initial testing (stage 1) of BAL101553, a novel tubulin binding agent, by the pediatric preclinical testing program.
Kolb EA; Gorlick R; Keir ST; Maris JM; Kang MH; Reynolds CP; Lock RB; Carol H; Wu J; Kurmasheva RT; Houghton PJ; Smith MA
Pediatr Blood Cancer; 2015 Jun; 62(6):1106-9. PubMed ID: 25407467
[TBL] [Abstract][Full Text] [Related]
9. Smac mimetic promotes glioblastoma cancer stem-like cell differentiation by activating NF-κB.
Tchoghandjian A; Jennewein C; Eckhardt I; Momma S; Figarella-Branger D; Fulda S
Cell Death Differ; 2014 May; 21(5):735-47. PubMed ID: 24488095
[TBL] [Abstract][Full Text] [Related]
10. Cortical and subventricular zone glioblastoma-derived stem-like cells display different molecular profiles and differential in vitro and in vivo properties.
Tchoghandjian A; Baeza-Kallee N; Beclin C; Metellus P; Colin C; Ducray F; Adélaïde J; Rougon G; Figarella-Branger D
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S608-19. PubMed ID: 21989663
[TBL] [Abstract][Full Text] [Related]
11. The effects of type I interferon on glioblastoma cancer stem cells.
Du Z; Cai C; Sims M; Boop FA; Davidoff AM; Pfeffer LM
Biochem Biophys Res Commun; 2017 Sep; 491(2):343-348. PubMed ID: 28728846
[TBL] [Abstract][Full Text] [Related]
12. The novel microtubule targeting agent BAL101553 in combination with radiotherapy in treatment-refractory tumor models.
Sharma A; Broggini-Tenzer A; Vuong V; Messikommer A; Nytko KJ; Guckenberger M; Bachmann F; Lane HA; Pruschy M
Radiother Oncol; 2017 Sep; 124(3):433-438. PubMed ID: 28797699
[TBL] [Abstract][Full Text] [Related]
13. Anti-migratory effect of vinflunine in endothelial and glioblastoma cells is associated with changes in EB1 C-terminal detyrosinated/tyrosinated status.
Rovini A; Gauthier G; Bergès R; Kruczynski A; Braguer D; Honoré S
PLoS One; 2013; 8(6):e65694. PubMed ID: 23750272
[TBL] [Abstract][Full Text] [Related]
14. The microtubule-targeted agent lisavanbulin (BAL101553) shows anti-tumor activity in lymphoma models.
Spriano F; Aresu L; Cascione L; Risi G; Arribas AJ; Napoli S; Forster-Gross N; Bachmann F; Engelhardt M; Lane H; Bertoni F
Am J Cancer Res; 2023; 13(5):2076-2086. PubMed ID: 37293172
[TBL] [Abstract][Full Text] [Related]
15. LGR5 promotes tumorigenicity and invasion of glioblastoma stem-like cells and is a potential therapeutic target for a subset of glioblastoma patients.
Xie Y; Sundström A; Maturi NP; Tan EJ; Marinescu VD; Jarvius M; Tirfing M; Jin C; Chen L; Essand M; Swartling FJ; Nelander S; Jiang Y; Uhrbom L
J Pathol; 2019 Feb; 247(2):228-240. PubMed ID: 30357839
[TBL] [Abstract][Full Text] [Related]
16. Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells.
Sunayama J; Sato A; Matsuda K; Tachibana K; Suzuki K; Narita Y; Shibui S; Sakurada K; Kayama T; Tomiyama A; Kitanaka C
Neuro Oncol; 2010 Dec; 12(12):1205-19. PubMed ID: 20861085
[TBL] [Abstract][Full Text] [Related]
17. miR128-1 inhibits the growth of glioblastoma multiforme and glioma stem-like cells via targeting BMI1 and E2F3.
Shan ZN; Tian R; Zhang M; Gui ZH; Wu J; Ding M; Zhou XF; He J
Oncotarget; 2016 Nov; 7(48):78813-78826. PubMed ID: 27705931
[TBL] [Abstract][Full Text] [Related]
18. CXCR4 antagonism sensitizes cancer cells to novel indole-based MDM2/4 inhibitors in glioblastoma multiforme.
Daniele S; La Pietra V; Piccarducci R; Pietrobono D; Cavallini C; D'Amore VM; Cerofolini L; Giuntini S; Russomanno P; Puxeddu M; Nalli M; Pedrini M; Fragai M; Luchinat C; Novellino E; Taliani S; La Regina G; Silvestri R; Martini C; Marinelli L
Eur J Pharmacol; 2021 Apr; 897():173936. PubMed ID: 33581134
[TBL] [Abstract][Full Text] [Related]
19. A Phase 1 study of BAL101553, a novel tumor checkpoint controller targeting microtubules, administered as 48-h infusion in adult patients with advanced solid tumors.
Joerger M; Stathis A; Metaxas Y; Hess D; Mantiero M; Mark M; Volden M; Kaindl T; Engelhardt M; Larger P; Lane H; Hafner P; Levy N; Stuedeli S; Sessa C; von Moos R
Invest New Drugs; 2020 Aug; 38(4):1067-1076. PubMed ID: 31471863
[TBL] [Abstract][Full Text] [Related]
20. Differential expression of miR16 in glioblastoma and glioblastoma stem cells: their correlation with proliferation, differentiation, metastasis and prognosis.
Tian R; Wang J; Yan H; Wu J; Xu Q; Zhan X; Gui Z; Ding M; He J
Oncogene; 2017 Oct; 36(42):5861-5873. PubMed ID: 28628119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
